Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Pharmaceuticals
Pharma
Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Legend's CEO resigned. Merck deleted a trial plan to combine its PD-1xVEGF bispecific with its TROP2 ADC. Otsuka's novel ADHD med wins FDA nod.
Angus Liu
Jul 31, 2026 9:00am
2 FDA citations trouble Hengrui, Elevar’s liver cancer combo
Jul 28, 2026 3:02pm
GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia
Jul 17, 2026 9:38am
Huahai poaches quality chief from Hengrui amid FDA citations
Jul 16, 2026 4:11pm
FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time
Jul 10, 2026 10:55am
AZ's China deals, Kailera-Hengrui—Fierce Pharma Asia
Jul 10, 2026 8:51am
